Promising prostate cancer combo study halted early
NCT ID NCT05009290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial enrolled 391 participants and aimed to see if the combination could eliminate all cancer in the removed prostate or delay the spread of cancer. The study was terminated early, so final results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HIGH-RISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER WHO ARE CANDIDATES FOR RADICAL PROSTATECTOMY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer center
Shanghai, Shanghai Municipality, China